致病性完全功能丧失型DYRK1B变异导致与2型糖尿病相关的单基因肥胖
在9353名肥胖和2型糖尿病病例对照研究参与者中测序DYRK1B,识别65个罕见杂合变异,经体外功能分析和ACMG标准判定20个致病/可能致病变异,其中6个为完全抑制性(P/LP-null)。P/LP-null变异与BMI升高、肥胖风险、空腹血糖升高和2型糖尿病风险相关,而P/LP变异对血糖稳态无影响。
要点
- P/LP-null DYRK1B变异与肥胖风险相关,比值比为7.9(95%CI 1.2-155)。
- P/LP-null DYRK1B变异与2型糖尿病风险相关,比值比为4.8(95%CI 0.85-37)。
- P/LP DYRK1B变异对血糖稳态无影响。
核心结论
- P/LP、完全功能丧失型DYRK1B变异导致与2型糖尿病相关的单基因肥胖。
- 本研究强调进行功能评估以准确确定P/LP DYRK1B变异实际效应的重要性。
研究设计与样本
- 从肥胖和2型糖尿病病例对照研究中纳入9353名参与者进行DYRK1B测序。
- 每个DYRK1B变异均进行体外功能评估。
- 使用美国医学遗传学与基因组学学会(ACMG)标准判定变异致病性。
- 使用校正混合效应评分检验评估致病或可能致病(P/LP)变异对代谢特征的影响。
主要发现
- 识别65个罕见杂合DYRK1B变异,与肥胖或2型糖尿病无关联。
- 功能分析后确定20个P/LP变异,包括6个对DYRK1B活性显示完全抑制效应的变异(P/LP-null)。
- P/LP和P/LP-null DYRK1B变异均与BMI升高和肥胖风险相关,但P/LP-null变异影响更明显(效应8.0 ± 3.2,比值比7.9 [95% CI 1.2-155])。
- P/LP-null变异与空腹血糖升高和2型糖尿病风险相关(效应2.9 ± 1.0,比值比4.8 [95% CI 0.85-37])。
- P/LP变异对血糖稳态无影响。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Rare variants in DYRK1B have been described in some patients with central obesity, type 2 diabetes, and early-onset coronary disease. Owing to the limited number of conducted studies, the broader impact of DYRK1B variants on a larger scale has yet to be investigated. RESEARCH DESIGN AND METHODS: DYRK1B was sequenced in 9,353 participants from a case-control study for obesity and type 2 diabetes. Each DYRK1B variant was functionally assessed in vitro. Variant pathogenicity was determined using criteria from the American College of Medical Genetics and Genomics (ACMG). The effect of pathogenic or likely pathogenic (P/LP) variants on metabolic traits was assessed using adjusted mixed-effects score tests. RESULTS: Sixty-five rare, heterozygous DYRK1B variants were identified and were not associated with obesity or type 2 diabetes. Following functional analyses, 20 P/LP variants were pinpointed, including 6 variants that exhibited a fully inhibitory effect (P/LP-null) on DYRK1B activity. P/LP and P/LP-null DYRK1B variants were associated with increased BMI and obesity risk; however, the impact was notably more pronounced for the P/LP-null variants (effect of 8.0 ± 3.2 and odds ratio of 7.9 [95% CI 1.2-155]). Furthermore, P/LP-null variants were associated with higher fasting glucose and type 2 diabetes risk (effect of 2.9 ± 1.0 and odds ratio of 4.8 [95% CI 0.85-37]), while P/LP variants had no effect on glucose homeostasis. CONCLUSIONS: P/LP, total loss-of-function DYRK1B variants cause monogenic obesity associated with type 2 diabetes. This study underscores the significance of conducting functional assessments in order to accurately ascertain the tangible effects of P/LP DYRK1B variants.
引用
- Folon L, Baron M, Scherrer V, et al. Pathogenic, Total Loss-of-Function DYRK1B Variants Cause Monogenic Obesity Associated With Type 2 Diabetes. Diabetes Care. 2024. PMID: 38170957. doi:10.2337/dc23-1851
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。